Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 12, 2014 - Issue 2
Submit an article Journal homepage
94
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV

Natalia Lorna LauferInstituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires - CONICET, Buenos Aires, Argentina;Hospital J.A. Fernández, Buenos Aires, ArgentinaCorrespondence[email protected]
&
Jürgen Kurt RockstrohDepartment of Medicine I, University of Bonn, Bonn, Germany
Pages 157-164 | Published online: 18 Dec 2013

References

  • Lavanchy D. The global burden of hepatitis C. Liver Int. 29(Suppl. 1), 74–81 (2009).
  • Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44(1 Suppl.), S6–S9 (2006).
  • Soriano V, Mocroft A, Rockstroh J et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J. Infect. Dis. 198(9), 1337–1344 (2008).
  • Laufer N, Quarleri J, Bouzas MB et al. Hepatitis B virus, hepatitis C virus and HIV coinfection among people living with HIV/AIDS in Buenos Aires, Argentina. Sex. Trans. Dis. 37(5), 342–343 (2010).
  • Bolcic F, Jones LR, Laufer N, Quarleri J. Molecular characterization of hepatitis C virus genotype 4 sequences in HIV-coinfected patients from Argentina. J. Med. Virol. 83(6), 935–940 (2011).
  • Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res. 85(1), 303–315 (2010).
  • Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30(4), 1054–1058 (1999).
  • Poynard T, Mathurin P, Lai CL et al. A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 38(3), 257–265 (2003).
  • Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 50(10), 1387–1396 (2010).
  • Smith C, Sabin CA, Lundgren JD et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24(10), 1537–1548 (2010).
  • Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426(6963), 186–189 (2003).
  • Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011).
  • Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405–2416 (2011).
  • Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J. Infect. Dis. 207(Suppl. 1), S26–S32 (2013).
  • Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr. Top. Microbiol. Immunol. 369, 321–342 (2013).
  • Llinas-Brunet M, Bailey MD, Goudreau N et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J. Med. Chem. 53(17), 6466–6476 (2010).
  • White PW, Llinas-Brunet M, Amad M et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 54(11), 4611–4618 (2010).
  • Manns MP, Bourliere M, Benhamou Y et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 54(6), 1114–1122 (2011).
  • Duan J, Yong CL, Garneau M et al. Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor. Xenobiotica 42(2), 164–172 (2012).
  • White PW, Llinas-Brunet M, Amad M et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 54(11), 4611–4618 (2010).
  • Sabo J, Kashuba A, Ballow C et al.Cytochrome P450 (CYP) Interactions with the HCV Protease Inhibitor Faldaprevir (BI 201335) in Healthy Volunteers. Presented at: The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 9–12 September 2012.
  • Sane R, Podila L, Mathur A et al. Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI201335. In: abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 1236. J. Hepatol. 54(Suppl. 1), S488 (2011).
  • Sabo J, Kort J, Haschke M et al. pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the hepatitis C virus protease inhibitor faldaprevir in healthy volunteers. Presented at: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA, 3–6 March 2013 ( Abstract 35).
  • Poster sessions. Hepatology 58(S1), 92A–207A (2013).
  • Kukolj G, McGibbon GA, McKercher G et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 280(47), 39260–39267 (2005).
  • Zeuzem S, Asselah T, Angus P et al. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antiviral Ther. doi:10.3851/IMP2567 (2013) ( Epub ahead of print).
  • Zeuzem S, Soriano V, Asselah T et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369(7), 630–639 (2013).
  • Sulkowski MS, Bourliere M, Bronowicki JP et al. Faldaprevir combined with peginterferon Alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 57(6), 2155–2163 (2013).
  • Sulkowski MS, Asselah T, Lalezari J et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 57(6), 2143–2154 (2013).
  • Dieterich D, Asselah T, Guyader D et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naïve patients with chronic genotype-1 HCV infection. Presented at: 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011). San Francisco, CA, USA, 4–8 November 2011 ( Abstract 36).
  • Ferenci P, Asselah T, Foster GR et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised double blind placebo-controlled phase III trial. Presented at: 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam, the Netherlands, 24–28 April 2013 ( Abstract 1416).
  • Dieterich D, Soriano V, Nelson M et al. STARTVerso4: high rates of early virologic response in HCV genotype 1/HIV-coinfected patients treated with faldaprevir plus PegIFN and RBV. CROI 2013. Atlanta, GA, USA, 3–6 March (2013).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.